# A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

> **NCT06804824** · PHASE1 · RECRUITING · sponsor: **Vividion Therapeutics, Inc.** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** VVD-159642
- **DRUG:** Sotorasib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT06804824
- **Lead sponsor:** Vividion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06804824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06804824, "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06804824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*